ADUS
Price
$122.50Alerts
Change
+$1.43 (+1.18%)
Updated
Nov 20 closing price
Capitalization
2.32B
100 days until earnings call
Intraday BUY SELL Signals
ASTH
Price
$28.90Alerts
Change
+$0.22 (+0.77%)
Updated
Nov 20 closing price
Capitalization
1.74B
96 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ADUS vs ASTH

ADUS vs ASTH Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ADUS vs. ASTH commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADUS is a Hold and ASTH is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ADUS with price predictions
Nov 20, 2026

ADUS sees MACD Histogram crosses below signal line

ADUS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 33 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 72%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ADUS moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 19 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 63%.

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADUS as a result. In 59 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.

ADUS broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

ADUS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ADUS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 45%.

Following a +1.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADUS advanced for three days, in 206 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

The Aroon Indicator entered an Uptrend today. In 135 of 218 cases where ADUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ADUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 45 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.022) is normal, around the industry mean (204.532). P/E Ratio (21.433) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.983) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (1.483) is also within normal values, averaging (2.688).

The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for ASTH with price predictions
Nov 20, 2026

ASTH in -10.35% downward trend, sliding for three consecutive days on November 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ASTH declined for three days, in 232 of 300 cases, the price declined further within the following month. The odds of a continued downward trend are 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASTH as a result. In 62 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for ASTH turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 29 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

ASTH moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ASTH crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 57%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASTH advanced for three days, in 240 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

ASTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 136 of 195 cases where ASTH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ASTH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.099) is normal, around the industry mean (204.532). P/E Ratio (42.878) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (0.485) is also within normal values, averaging (2.688).

The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

FUNDAMENTALS RATINGS
ADUS vs ASTH: Fundamental Ratings
ADUS
ASTH
OUTLOOK RATING
1..100
9253
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
45100
SMR RATING
1..100
7283
PRICE GROWTH RATING
1..100
4264
P/E GROWTH RATING
1..100
5977
SEASONALITY SCORE
1..100
5034

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADUS's Valuation (72) in the Medical Or Nursing Services industry is in the same range as ASTH (80) in the null industry. This means that ADUS’s stock grew similarly to ASTH’s over the last 12 months.

ADUS's Profit vs Risk Rating (45) in the Medical Or Nursing Services industry is somewhat better than the same rating for ASTH (100) in the null industry. This means that ADUS’s stock grew somewhat faster than ASTH’s over the last 12 months.

ADUS's SMR Rating (72) in the Medical Or Nursing Services industry is in the same range as ASTH (83) in the null industry. This means that ADUS’s stock grew similarly to ASTH’s over the last 12 months.

ADUS's Price Growth Rating (42) in the Medical Or Nursing Services industry is in the same range as ASTH (64) in the null industry. This means that ADUS’s stock grew similarly to ASTH’s over the last 12 months.

ADUS's P/E Growth Rating (59) in the Medical Or Nursing Services industry is in the same range as ASTH (77) in the null industry. This means that ADUS’s stock grew similarly to ASTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADUSASTH
RSI
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
70%
MACD
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 6 days ago
76%
Declines
ODDS (%)
Bearish Trend 4 days ago
62%
Bearish Trend 3 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
70%
COMPARISON
Comparison
Nov 22, 2026
Stock price -- (ADUS: $122.50 vs. ASTH: $28.90)
Brand notoriety: ADUS and ASTH are both not notable
Both companies represent the Hospital/Nursing Management industry
Current volume relative to the 65-day Moving Average: ADUS: 146% vs. ASTH: 101%
Market capitalization -- ADUS: $2.32B vs. ASTH: $1.74B
ADUS [@Hospital/Nursing Management] is valued at $2.32B. ASTH’s [@Hospital/Nursing Management] market capitalization is $1.74B. The market cap for tickers in the [@Hospital/Nursing Management] industry ranges from $20.9K to $107.17B. The average market capitalization across the [@Hospital/Nursing Management] industry is $5.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADUS’s FA Score shows that 0 FA rating(s) are green while ASTH’s FA Score has 0 green FA rating(s).

  • ADUS’s FA Score: 0 green, 5 red.
  • ASTH’s FA Score: 0 green, 5 red.
According to our system of comparison, ADUS is a better buy in the long-term than ASTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADUS’s TA Score shows that 5 TA indicator(s) are bullish while ASTH’s TA Score has 5 bullish TA indicator(s).

  • ADUS’s TA Score: 5 bullish, 5 bearish.
  • ASTH’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ASTH is a better buy in the short-term than ADUS.

Price Growth

ADUS (@Hospital/Nursing Management) experienced а -0.41% price change this week, while ASTH (@Hospital/Nursing Management) price change was -9.12% for the same time period.

The average weekly price growth across all stocks in the @Hospital/Nursing Management industry was -11.67%. For the same industry, the average monthly price growth was -11.86%, and the average quarterly price growth was +0.44%.

Reported Earning Dates

ADUS is expected to report earnings on Mar 01, 2027.

ASTH is expected to report earnings on Feb 25, 2027.

Industries' Descriptions

@Hospital/Nursing Management (-11.67% weekly)

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ADUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADUS has been loosely correlated with PNTG. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ADUS jumps, then PNTG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADUS
1D Price
Change %
ADUS100%
+1.18%
PNTG - ADUS
44%
Loosely correlated
+1.61%
HCSG - ADUS
38%
Loosely correlated
-0.20%
NHC - ADUS
36%
Loosely correlated
+1.18%
ENSG - ADUS
34%
Loosely correlated
-0.15%
CON - ADUS
32%
Poorly correlated
+0.94%
More

ASTH and

Correlation & Price change

A.I.dvisor tells us that ASTH and PNTG have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ASTH and PNTG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASTH
1D Price
Change %
ASTH100%
+0.77%
PNTG - ASTH
32%
Poorly correlated
+1.61%
HCA - ASTH
30%
Poorly correlated
+3.31%
HCSG - ASTH
29%
Poorly correlated
-0.20%
STLN - ASTH
28%
Poorly correlated
-5.66%
ADUS - ASTH
26%
Poorly correlated
+1.18%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INVA18.41N/A
N/A
Innoviva
DSX2.21-0.04
-1.78%
Diana Shipping
LVO2.61-0.10
-3.69%
LiveOne Inc
MSM103.13-4.12
-3.84%
MSC Industrial Direct Co
ETN311.33-19.24
-5.82%
Eaton Corp